CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.

MLA

Yao, Yao, et al. “CDK7 Controls E2F- and MYC-Driven Proliferative and Metabolic Vulnerabilities in Multiple Myeloma.” Blood, vol. 141, no. 23, June 2023, pp. 2841–52. EBSCOhost, https://doi.org/10.1182/blood.2022018885.

APA

Yao, Y., Ng, J. F., Park, W. D., Samur, M., Morelli, E., Encinas Mayoral, J., Chyra, Z., Xu, Y., Derebail, S., Epstein, C., Nabet, B., Chesi, M., Gray, N. S., Young, R. A., Kwiatkowski, N., Mitsiades, C., Anderson, K. C., Lin, C. Y., Munshi, N. C., & Fulciniti, M. (2023). CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. Blood, 141(23), 2841–2852. https://doi.org/10.1182/blood.2022018885

Chicago

Yao, Yao, Jessica Fong Ng, Woojun Daniel Park, Mehmet Samur, Eugenio Morelli, Jessica Encinas Mayoral, Zuzana Chyra, et al. 2023. “CDK7 Controls E2F- and MYC-Driven Proliferative and Metabolic Vulnerabilities in Multiple Myeloma.” Blood 141 (23): 2841–52. doi:10.1182/blood.2022018885.